CD52 and graft versus host disease: ALLO-715 is a genetically modified anti-BCMA CAR-T product which employed TALEN technology to disrupt the TCR constant gene and CD52 gene to prevent GVHD and allow the use of anti-CD52 based lymphodepletion (194).